Cargando…
Treatment of neovascular age-related macular degeneration in patients with diabetes
The number of patients with type 2 diabetes continues to rise; an anticipated 300 million people will be affected by 2025. The immense social and economic burden of the condition is exacerbated by the initial asymptomatic nature of type 2 diabetes, resulting in a high prevalence of micro-and macrova...
Autores principales: | Cummings, Michael, Cunha-Vaz, José |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2693968/ https://www.ncbi.nlm.nih.gov/pubmed/19668728 |
Ejemplares similares
-
Faricimab for the Treatment of Diabetic Macular Edema and Neovascular Age-Related Macular Degeneration
por: Ferro Desideri, Lorenzo, et al.
Publicado: (2023) -
Ranibizumab in neovascular age-related macular degeneration
por: Eng, Kenneth T, et al.
Publicado: (2006) -
Treatment of neovascular age-related macular degeneration: Current therapies
por: Augustin, Albert J, et al.
Publicado: (2009) -
Profile of conbercept in the treatment of neovascular age-related macular degeneration
por: Lu, Xinmin, et al.
Publicado: (2015) -
Comparative effectiveness of aflibercept for the treatment of patients with neovascular age-related macular degeneration
por: Thomas, Michael, et al.
Publicado: (2013)